Efficient NQO1 substrates are potent and selective anticancer agents

ACS Chemical Biology

Volumn 8, Issue 10, 2013, Pages 2173-2183

  Parkinson, Elizabeth I ^a   Bair, Joseph S ^a   Cismesia, Megan ^a   Hergenrother, Paul J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APAZIQUONE; BETA LAPACHONE; DEOXYNYBOQUINONE; FLAVOPROTEIN; GEFITINIB; IMATINIB; MITOMYCIN; OXIDOREDUCTASE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RH1; RUFOCROMOMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; NQO1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; ONCOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; APOPTOSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CATALYTIC DOMAIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, MOLECULAR; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; QUINONES; SUBSTRATE SPECIFICITY;

EID: 84886519739     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4005832     Document Type: Article

References (56)

1. Siegel, D., Reigan, P., and Ross, D. One- and two-electron-mediated reduction of quinones: Enzymology and toxicological implications. In Advances in Bioactivation Research; Springer: New York, 2008; Vol. IX, pp 1-29.
2. Danson, S., Ward, T. H., Butler, J., and Ranson, M. (2004) DT-diaphorase: A target for new anticancer drugs Cancer Treat. Rev. 30, 437-449
3. Begleiter, A. and Fourie, J. (2004) Induction of NQO1 in cancer cells Methods Enzymol. 382, 320-351
4. Deller, S., Macheroux, P., and Sollner, S. (2008) Flavin-dependent quinone reductases Cell. Mol. Life Sci. 65, 141-160
5. Guo, W., Reigan, P., Siegel, D., and Ross, D. (2008) Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: Relevance for toxicity and mechanism of action Drug Metab. Dispos. 36, 2050-2057
6. Long, D. J., 2nd, Waikel, R. L., Wang, X. J., Roop, D. R., and Jaiswal, A. K. (2001) NAD(P)H:Quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin J. Natl. Cancer Inst. 93, 1166-1170
7. Siegel, D., Gustafson, D. L., Dehn, D. L., Han, J. Y., Boonchoong, P., Berliner, L. J., and Ross, D. (2004) NAD(P)H:Quinone oxidoreductase 1: Role as a superoxide scavenger Mol. Pharmacol. 65, 1238-1247
8. Siegel, D., Yan, C., and Ross, D. (2012) NAD(P)H:Quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones Biochem. Pharmacol. 83, 1033-1040
9. Schlager, J. J. and Powis, G. (1990) Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol Int. J. Cancer 45, 403-409
10. Marin, A., Lopez de Cerain, A., Hamilton, E., Lewis, A. D., Martinez-Penuela, J. M., Idoate, M. A., and Bello, J. (1997) DT-diaphorase and cytochrome B5 reductase in human lung and breast tumors Br. J. Cancer 76, 923-929
11. Smitskamp-Wilms, E., Giaccone, G., Pinedo, H. M., van der Laan, B. F., and Peters, G. J. (1995) DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br. J. Cancer 72, 917-921
12. Bey, E. A., Bentle, M. S., Reinicke, K. E., Dong, Y., Yang, C. R., Girard, L., Minna, J. D., Bornmann, W. G., Gao, J., and Boothman, D. A. (2007) An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone Proc. Natl. Acad. Sci. U.S.A. 104, 11832-11837
13. Lewis, A. M., Ough, M., Hinkhouse, M. M., Tsao, M. S., Oberley, L. W., and Cullen, J. J. (2005) Targeting NAD(P)H:Quinone oxidoreductase (NQO1) in pancreatic cancer Mol. Carcinog. 43, 215-224
14. Awadallah, N. S., Dehn, D., Shah, R. J., Russell Nash, S., Chen, Y. K., Ross, D., Bentz, J. S., and Shroyer, K. R. (2008) NQO1 expression in pancreatic cancer and its potential use as a biomarker Appl. Immunohistochem. Mol. Morphol. 16, 24-31
15. Cullen, J. J., Hinkhouse, M. M., Grady, M., Gaut, A. W., Liu, J., Zhang, Y. P., Weydert, C. J., Domann, F. E., and Oberley, L. W. (2003) Dicumarol inhibition of NADPH:Quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism Cancer Res. 63, 5513-5520
16. Siegel, D., Beall, H., Senekowitsch, C., Kasai, M., Arai, H., Gibson, N. W., and Ross, D. (1992) Bioreductive activation of mitomycin C by DT-diaphorase Biochemistry 31, 7879-7885
17. Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., and Lewis, A. D. (1996) Reductase enzyme expression across the national cancer institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9 J. Natl. Cancer Inst. 88, 259-269
18. Nemeikaite-Ceniene, A., Sarlauskas, J., Anusevicius, Z., Nivinskas, H., and Cenas, N. (2003) Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:Quinone oxidoreductase (NQO1) and oxidative stress Arch. Biochem. Biophys. 416, 110-118
19. Dehn, D. L., Inayat-Hussain, S. H., and Ross, D. (2005) RH1 induces cellular damage in an NAD(P)H:Quinone oxidoreductase 1-dependent manner: Relationship between DNA cross-linking, cell cycle perturbations, and apoptosis J. Pharmacol. Exp. Ther. 313, 771-779
20. Dehn, D. L., Winski, S. L., and Ross, D. (2004) Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:Quinone oxidoreductase-directed antitumor quinones: Evaluation of the activity of RH1 Clin. Cancer Res. 10, 3147-3155
21. Walton, M. I., Bibby, M. C., Double, J. A., Plumb, J. A., and Workman, P. (1992) DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas Eur. J. Cancer 28A, 1597-1600
22. Plumb, J. A., Gerritsen, M., Milroy, R., Thomson, P., and Workman, P. (1994) Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines Int. J. Radiat., Oncol., Biol., Phys. 29, 295-299
23. Beall, H. D., Liu, Y., Siegel, D., Bolton, E. M., Gibson, N. W., and Ross, D. (1996) Role of NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin Biochem. Pharmacol. 51, 645-652
24. Pink, J. J., Planchon, S. M., Tagliarino, C., Varnes, M. E., Siegel, D., and Boothman, D. A. (2000) NAD(P)H:Quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity J. Biol. Chem. 275, 5416-5424
25. Ross, D., Beall, H. D., Siegel, D., Traver, R. D., and Gustafson, D. L. (1996) Enzymology of bioreductive drug activation Br. J. Cancer Suppl. 27, S1-8
26. Keyes, S. R., Fracasso, P. M., Heimbrook, D. C., Rockwell, S., Sligar, S. G., and Sartorelli, A. C. (1984) Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1 Cancer Res. 44, 5638-5643
27. Yan, C., Kepa, J. K., Siegel, D., Stratford, I. J., and Ross, D. (2008) Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) Mol. Pharmacol. 74, 1657-1665
28. Tudor, G., Alley, M., Nelson, C. M., Huang, R., Covell, D. G., Gutierrez, P., and Sausville, E. A. (2005) Cytotoxicity of RH1: NAD(P)H:Quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction Anticancer Drugs 16, 381-391
29. Yee, S. B. and Pritsos, C. A. (1997) Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase Arch. Biochem. Biophys. 347, 235-241
30. Plumb, J. A., Gerritsen, M., and Workman, P. (1994) DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9 Br. J. Cancer 70, 1136-1143
31. Plumb, J. A. and Workman, P. (1994) Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity Int. J. Cancer 56, 134-139
32. Gutierrez, P. L. (2000) The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: A review Free Radical Biol. Med. 29, 263-275
33. Danson, S. J., Johnson, P., Ward, T. H., Dawson, M., Denneny, O., Dickinson, G., Aarons, L., Watson, A., Jowle, D., Cummings, J., Robson, L., Halbert, G., Dive, C., and Ranson, M. (2011) Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1 Ann. Oncol. 22, 1653-1660
34. Loadman, P. M., Bibby, M. C., and Phillips, R. M. (2002) Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9 Br. J. Pharmacol. 137, 701-709
35. Miao, X. S., Song, P., Savage, R. E., Zhong, C., Yang, R. Y., Kizer, D., Wu, H., Volckova, E., Ashwell, M. A., Supko, J. G., He, X., and Chan, T. C. (2008) Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl- 2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; β-lapachone) in whole blood Drug Metab. Dispos. 36, 641-648
36. Smith, G. M., Gordon, J. A., Sewell, I. A., and Ellis, H. (1967) A trial of streptonigrin in the treatment of advanced malignant disease Br. J. Cancer 21, 295-301
37. Bair, J. S., Palchaudhuri, R., and Hergenrother, P. J. (2010) Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death J. Am. Chem. Soc. 132, 5469-5478
38. Huang, X., Dong, Y., Bey, E. A., Kilgore, J. A., Bair, J. S., Li, L. S., Patel, M., Parkinson, E. I., Wang, Y., Williams, N. S., Gao, J., Hergenrother, P. J., and Boothman, D. A. (2012) An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis Cancer Res. 72, 3038-3047
39. Asher, G., Dym, O., Tsvetkov, P., Adler, J., and Shaul, Y. (2006) The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol Biochemistry 45, 6372-6378
40. Winski, S. L., Faig, M., Bianchet, M. A., Siegel, D., Swann, E., Fung, K., Duncan, M. W., Moody, C. J., Amzel, L. M., and Ross, D. (2001) Characterization of a mechanism-based inhibitor of NAD(P)H:Quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches Biochemistry 40, 15135-15142
41. Yan, C., Shieh, B., Reigan, P., Zhang, Z., Colucci, M. A., Chilloux, A., Newsome, J. J., Siegel, D., Chan, D., Moody, C. J., and Ross, D. (2009) Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target Mol. Pharmacol. 76, 163-172
42. Gonzalez-Aragon, D., Alcain, F. J., Ariza, J., Jodar, L., Barbarroja, N., Lopez-Pedrera, C., and Villalba, J. M. (2010) ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:Quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK Chem. Biol. Interact. 186, 174-183
43. Keyes, S. R., Rockwell, S., and Sartorelli, A. C. (1989) Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells Cancer Res. 49, 3310-3313
44. Dehn, D. L., Siegel, D., Swann, E., Moody, C. J., and Ross, D. (2003) Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:Quinone oxidoreductase 1, in cellular systems Mol. Pharmacol. 64, 714-720
45. Hosoda, S., Nakamura, W., and Hayashi, K. (1974) Properties and reaction mechanism of DT diaphorase from rat liver J. Biol. Chem. 249, 6416-6423
46. De Haan, L. H., Boerboom, A. M., Rietjens, I. M., van Capelle, D., De Ruijter, A. J., Jaiswal, A. K., and Aarts, J. M. (2002) A physiological threshold for protection against menadione toxicity by human NAD(P)H:Quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells Biochem. Pharmacol. 64, 1597-1603
47. Li, L. S., Bey, E. A., Dong, Y., Meng, J., Patra, B., Yan, J., Xie, X. J., Brekken, R. A., Barnett, C. C., Bornmann, W. G., Gao, J., and Boothman, D. A. (2011) Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy Clin. Cancer Res. 17, 275-285
48. Hasinoff, B. B. and Begleiter, A. (2006) The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells Free Radical Res. 40, 974-978
49. Li, R., Bianchet, M. A., Talalay, P., and Amzel, L. M. (1995) The three-dimensional structure of NAD(P)H:Quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction Proc. Natl. Acad. Sci. U.S.A. 92, 8846-8850
50. Faig, M., Bianchet, M. A., Talalay, P., Chen, S., Winski, S., Ross, D., and Amzel, L. M. (2000) Structures of recombinant human and mouse NAD(P)H:Quinone oxidoreductases: Species comparison and structural changes with substrate binding and release Proc. Natl. Acad. Sci. U.S.A. 97, 3177-3182
51. Faig, M., Bianchet, M. A., Winski, S., Hargreaves, R., Moody, C. J., Hudnott, A. R., Ross, D., and Amzel, L. M. (2001) Structure-based development of anticancer drugs: Complexes of NAD(P)H:Quinone oxidoreductase 1 with chemotherapeutic quinones Structure 9, 659-667
52. Vilar, S., Cozza, G., and Moro, S. (2008) Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery Curr. Top. Med. Chem. 8, 1555-1572
53. Mendoza, M. F., Hollabaugh, N. M., Hettiarachchi, S. U., and McCarley, R. L. (2012) Human NAD(P)H:Quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups Biochemistry 51, 8014-8026
54. Eickelmann, P., Schulz, W. A., Rohde, D., Schmitz-Drager, B., and Sies, H. (1994) Loss of heterozygosity at the NAD(P)H:Quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line Biol. Chem. Hoppe-Seyler 375, 439-445
55. Kelsey, K. T., Ross, D., Traver, R. D., Christiani, D. C., Zuo, Z. F., Spitz, M. R., Wang, M., Xu, X., Lee, B. K., Schwartz, B. S., and Wiencke, J. K. (1997) Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy Br. J. Cancer 76, 852-854
56. Vichai, V. and Kirtikara, K. (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening Nat. Protocols 1, 1112-1116